Abstracts Archive - Page 1422 of 2607 - ACR Meeting Abstracts

Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis
Mauro Galeazzi¹, Gian Domenico Sebastiani², Jürgen Wollenhaupt³, Jean Dudler⁴, Christof Specker⁵, Reinhard Voll⁶, Pascal Zufferey⁷, Piercarlo Sarzi Puttini⁸, Ombretta Viapiana⁹ and Franziska Bootz¹⁰, ¹Rheumatology, University Hospital of Siena, Siena, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, ⁶Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁸Rheumatology, Luigi Sacco Hospital, Milan, Italy, ⁹University Hospital Verona, Verona, Italy, ¹⁰Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland
Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Sander Strengholt⁶, Ryan DeMasi⁷ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
Abstract Number: 523 • 2017 ACR/ARHP Annual Meeting
Prevalence of Occult Hepatitis B Carrier Status and Its Associated Risk Factors in Patients with Rheumatic Diseases Undergoing Biological Therapies
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan¹, Sau Mei Tse¹ and Chi Hung To³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, ³Medicine, Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence of occult hepatitis B carrier status and its associated factors in patients with rheumatic diseases undergoing biological therapies Methods: Consecutive…
Abstract Number: 524 • 2017 ACR/ARHP Annual Meeting
Predictors of Mortality in RA Patients before Biologic Therapy
Debora Cordeiro Rosario¹, Camila Nobre Bulhoes¹, Rodrigo Peres Toledo¹, Karina Bonfiglioli², Ana C.M. Ribeiro³, Julio C. B. Moraes², Carla G.S. Saad², Clovis A Silva⁴, Eloisa Bonfa⁵ and Nadia E Aikawa², ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Several studies have evaluated mortality risk factors in rheumatoid arthritis (RA) but that are no data regarding baseline predictors of mortality in patients under…
Abstract Number: 525 • 2017 ACR/ARHP Annual Meeting
Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center
Richard Meehan¹, Isabelle Amigues², David Muram³, Eric Hoffman⁴, Jim Crooks⁵, Tho Truong⁶ and Pearlanne Zelarney⁷, ¹MEDICINE, National Jewish Health, Denver, CO, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Medicine/Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Rheumatology, National Jewish Health, Denver, CO, ⁷Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: The goal of therapy of rheumatoid arthritis (RA) is to achieve a state of low disease activity (LDA) or remission and reduce joint damage…
Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting
Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition
Eun Ha Kang¹, Yinzhu Jin², Sara Dejene³, Gregory Brill³, Rishi J. Desai², Jeffrey A. Sparks⁴ and Seoyoung C. Kim⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers², Sara Gale³, Micki Klearman³, Khaled Sarsour³ and Sebastian Schneeweiss², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Genentech, South San Francisco, CA
Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 529 • 2017 ACR/ARHP Annual Meeting
Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience
Edurne Guerrero Basterretxea¹, Maria Luz Garcia Vivar¹, Itziar Calvo Zorrilla¹, Oihane Ibarguengoitia², Eva Galíndez Agirregoikoa², Juan Maria Blanco Madrigal³, Esther Ruíz Lucea¹, Ignacio Torre Salaberri¹, Olaia Begoña Fernandez Berrizbeitia², Clara Eugenia Perez¹, Ana Rosa Intxaurbe Pellejero², Natalia Rivera-García⁴ and Iñigo Gorostiza Hormaetxe⁵, ¹RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, BILBAO, Spain, ³Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ⁴RESEARCH, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ⁵RESEARCH, Research Department. Basurto University Hospital, BILBAO, Spain
Background/Purpose: Use of biological therapy (BT) has dramatically improved Rheumatoid Arthritis (RA) management and outcomes for the last decade. Classic extraarticular manifestations are now uncommon,…
Abstract Number: 530 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Sumit Kunwar¹, Christopher E. Collins² and Florina Constantinescu², ¹Rheumatology, MedStar Washington Hospital Center, washington, DC, ²Rheumatology, MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Janus kinases (JAKs) play an important role in intracellular signaling for multiple cytokines in the pathogenesis of RA. Baricitinib is an oral, selective JAK…
Abstract Number: 531 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials
Natalia Zamora^1,2,3, Maria A. Lopez-Olivo¹, Jean Tayar¹, Robin Christensen² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: To explore the comparative effectiveness of tofacitinib or baricitinib in patients with rheumatoid arthritis (RA) following a systematic review of randomized trials, by performing…
Abstract Number: 532 • 2017 ACR/ARHP Annual Meeting
Genetic Predictors of Iguratimod Clinical Response and Toxicity in Patients with Rheumatoid Arthritis
Wenjing Xiao, Department of Rheumatology and Immunology, People’s Hospital, , Peking University, Beijing, Beijing, China
Background/Purpose: Iguratimod (IGU) is a novel DMARD in rheumatoid arthritis (RA). The purpose of this study was to identify genetic predictors of response and adverse…
Abstract Number: 533 • 2017 ACR/ARHP Annual Meeting
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Désirée van der Heijde¹, Jürgen Wollenhaupt², Stanley B Cohen³, Sander Strengholt⁴, Ketti Terry⁵, Ryan DeMasi⁶, Kenneth Kwok⁷, Irina Lazariciu⁸ and Lisy Wang⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸QuintilesIMS, Saint-Laurent, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The long-term safety and clinical efficacy of tofacitinib 5 and 10 mg…
Abstract Number: 534 • 2017 ACR/ARHP Annual Meeting
Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study
René Westhovens¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset² and Pille Harrison², ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 535 • 2017 ACR/ARHP Annual Meeting
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies
Ruediger Mueller¹, Hendrik Schulze-Koops², Daniel E Furst³, Stanley B Cohen⁴, Kenneth Kwok⁵, Anna Maniccia⁵, Lisy Wang⁶, Ermeg Akylbekova⁷ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Klinikum der Universität München, Munich, Germany, ³UCLA, Los Angeles, CA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷QuintilesIMS, Durham, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Efficacy and safety of tofacitinib 5 and 10 mg BID have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].